Biomass gasification is one of the most promising technologies for converting biomass, a renewable source, into an easily transportable and usable fuel. Two woody biomass fuels Agrol and willow, and ...one agriculture residue Dry Distiller’s Grains with Solubles (DDGS), have been tested using an atmospheric pressure 100 kWth steam-oxygen blown circulating fluidized bed gasifier (CFB). The effects of operational conditions (e.g. steam to biomass ratio (SBR), oxygen to biomass stoichiometric ratio (ER) and gasification temperature) and bed materials on the composition distribution of the product gas and tar formation from these fuels were investigated. Experimental results show that there is a significant variation in the composition of the product gas produced. Among all the experiments, the averaged concentration of H
2 obtained from Agrol, willow and DDGS over the temperature range from 800 to 820 °C was around 24 vol.%, 28 vol.% and 20 vol.% on a N
2 free basis, respectively. A fairly high amount of H
2S (∼2300 ppmv), COS (∼200 ppmv) and trace amounts of methyl mercaptan (<3 ppmv) on a N
2 free basis were obtained from DDGS. Due to a relatively high content of K and Cl in DDGS fuel, an alkali-getter (e.g. kaolin) was added to avoid agglomeration during gasification. Higher temperatures and SBR values were favorable for increasing the mole ratio of H
2 to CO and the tar decomposition but less advantageous for the formation of CH
4. Meanwhile, higher temperatures and SBR values also led to higher gas yields, whereas a higher SBR caused a lower carbon conversion efficiency (CCE%), cold gas efficiency (CGE%) and heating values of the product gas due to a high steam content in the product gas. From solid phase adsorption (SPA) results, the total tar content obtained from Agrol was the highest at around 12.4 g/Nm
3, followed by that from DDGS and willow gasification. The lowest tar content produced from Agrol, willow and DDGS using Austrian olivine (Bed 1) as bed materials was 5.7, 4.4 and 7.3 g/Nm
3, values which were obtained at a temperature of 730, 820 and 730 °C, SBR of 1.52, 1.14 and 1.10, and ER of 0.36, 0.39 and 0.37, respectively.
► Woody fuels and DDGS gasification in a steam-O
2 blown CFB gasifier was studied. ► Agglomeration occurred during DDGS gasification at high temperature without additive. ► High temperature and SBR value lowered tar content and increased H
2/CO molar ratio. ► Bed materials affected tar and H
2S formation to a certain extent.
Pain response after conventional external beam radiation therapy (cRT) in patients with painful bone metastases is observed in 60% to 70% of patients. The aim of the VERTICAL trial was to investigate ...whether stereotactic body radiation therapy (SBRT) improves pain response.
This single-center, phase 2, randomized controlled trial was conducted within the PRESENT cohort, which consists of patients referred for radiation therapy of bone metastases to our tertiary center. Cohort participants with painful bone metastases who gave broad informed consent for randomization were randomly assigned to cRT or SBRT. Only patients in the intervention arm received information about the trial and were offered SBRT (1 × 18 Gy, 3 × 10 Gy, or 5 × 7 Gy), which they could accept or refuse. Patients who refused SBRT underwent standard cRT (1 × 8 Gy, 5 × 4 Gy, or 10 × 3 Gy). Patients in the control arm were not informed. Primary endpoint was pain response at 3 months after radiation therapy. Secondary outcomes were pain response at any point within 3 months, mean pain scores, and toxicity. Data were analyzed intention to treat (ITT) and per protocol (PP). This trial was registered with Clinicaltrials.gov, NCT02364115.
Between January 29, 2015, and March 20, 2019, 110 patients were randomized. ITT analysis included 44 patients in the cRT arm and 45 patients in the SBRT arm. In the intervention arm, 12 patients (27%) declined SBRT, and 7 patients (16%) were unable to complete the SBRT treatment. In ITT, 14 of 44 patients (32%; 95% confidence interval CI, 18%-45%) in the control arm and 18 of 45 patients (40%; 95% CI, 26%-54%) in the SBRT arm reported a pain response at 3 months (P = .42). In PP, these proportions were 14 of 44 (32%; 95% CI, 18%-45%) and 12 of 23 patients (46%; 95% CI, 27%-66%), respectively (P = .55). In ITT, a pain response within 3 months was reported by 30 of 44 control patients (82%; 95% CI, 68%-90%) and 38 of 45 patients (84%; 95% CI, 71%-92%) in the SBRT arm (P = .12). In PP, these proportions were 36 of 44 (82%; 95% CI, 68%-90%) and 26 of 27 patients (96%; 95% CI; 81%-100%), respectively (P = .12). No grade 3 or 4 toxicity was observed in either arm.
SBRT did not significantly improve pain response in patients with painful bone metastases. One in 4 patients preferred to undergo cRT over SBRT, and 1 in 5 patients starting SBRT was unable to complete this treatment. Because of this selective dropout, which can be attributed to the character of the intervention, the trial was underpowered to detect the prespecified difference in pain response.
Syngas produced by gasification process of biomass fuels is an environmental friendly alternative to conventional petrochemical fuels for the production of electricity, hydrogen, synthetic ...transportation biofuels and other chemicals. However, the advanced utilization of syngas is significantly limited due to the contaminants which can seriously deactivate the catalysts used for downstream reaction such as steam reforming methane, Fischer–Tropsch synthesis and corrosion of downstream equipments such as a gas turbine. Among the contaminants, sulphur compounds produced in the gasification process, which are mainly H
2S with small amounts of COS, CS
2 and thiophenes depending on process conditions, must be removed. For biomass feedstock advances are required in the cleanup technologies and processes to upgrade the raw product gas with minimal impact on the overall process efficiency. Hot gas desulphurization (HGD) can improve the overall thermal efficiency due to the elimination of fuel gas cooling and associated heat exchangers. With this aim, the present review paper highlights currently developed methods used for desulphurization of hot gas produced from gasification process of solid fuels. The methods presented here are for both in situ and downstream sulphur capture. Also, the attention is paid to the regeneration of the used materials. In situ sulphur capture is mainly done by using calcium-based sorbents such as limestone and dolomite, whereas downstream sulphur capture is mainly focused on the use of regenerable single, mixed, and supported metal oxides. A comparison is indicated at the end to show the sulphur loading of various materials.
Significant comorbidities, advanced age, and a poor performance status prevent surgery and systemic treatment for many patients with localized (non-metastatic) pancreatic ductal adenocarcinoma ...(PDAC). These patients are currently treated with 'best supportive care'. Therefore, it is desirable to find a treatment option which could improve both disease control and quality of life in these patients. A brief course of high-dose high-precision radiotherapy i.e. stereotactic ablative body radiotherapy (SABR) may be feasible.
A nationwide multicenter trial performed within a previously established large prospective cohort (the Dutch Pancreatic cancer project; PACAP) according to the 'Trial within cohorts' (TwiCs) design. Patients enrolled in the PACAP cohort routinely provide informed consent to answer quality of life questionnaires and to be randomized according to the TwiCs design when eligible for a study. Patients with localized PDAC who are unfit for chemotherapy and surgery or those who refrain from these treatments are eligible. Patients will be randomized between SABR (5 fractions of 8 Gy) with 'best supportive care' and 'best supportive care' only. The primary endpoint is overall survival from randomization. Secondary endpoints include preservation of quality of life (EORTC-QLQ-C30 and -PAN26), NRS pain score response and WHO performance scores at baseline, and, 3, 6 and 12 months. Acute and late toxicity will be scored using CTCAE criteria version 5.0: assessed at baseline, day of last fraction, at 3 and 6 weeks, and 3, 6 and 12 months following SABR.
The PANCOSAR trial studies the added value of SBRT as compared to 'best supportive care' in patients with localized PDAC who are medically unfit to receive chemotherapy and surgery, or refrain from these treatments. This study will assess whether SABR, in comparison to best supportive care, can relieve or delay tumor-related symptoms, enhance quality of life, and extend survival in these patients.
Clinical trials, NCT05265663 , Registered March 3 2022, Retrospectively registered.
Abstract The incidence and mortality of breast cancer continues to rise rapidly in Asian countries. However, most of our current knowledge on breast cancer has been generated in Western populations. ...As the socio-economic profile, life style and culture of Asian and Western women are substantially different, and genetic backgrounds vary to some extent, we need to answer the question on whether to ‘adopt’ or ‘adapt’ Western knowledge before applying it in the Asian setting. It is generally accepted that breast cancer risk factors, which have mainly been studied in Western populations are similar worldwide. However, the presence of gene–environment or gene–gene interactions may alter their importance as causal factors across populations. Diagnostic and prognostic study findings, including breast cancer prediction rules, are increasingly shown to be ‘setting specific’ and must therefore be validated in Asian women before implementing them in clinical care in Asia. Interventional research findings from Caucasian patients may not be applicable in patients in Asia due to differences in tumour biology/profiles, metabolism of drugs and also health beliefs which can influence treatment acceptance and adherence. While breast cancer research in Asia is warranted in all domains of medical research, it is felt that for Asian breast cancer patients, needs are highest for diagnostic and prognostic studies. International clinical trials meanwhile need to include breast cancer patients from various Asian settings to provide an insight into the effectiveness of new treatment modalities in this part of the world.
•The interactions between tar and SOFCs at different temperatures are examined.•Both wet and dry conditions are considered for the interaction.•Carbon dioxide for the suppression of carbon deposition ...is examined.•Tar is partly or completely reformed at the anode.
This paper presents an experimental study of the effects of tar on the performance of SOFCs with Ni/GDC anodes. Various operating temperature levels (700, 800 and 900°C) under both dry and wet conditions were employed in this study. Polarization behavior, electrochemical impedance spectroscopy, and cell voltage degradation were analyzed to evaluate the cell performance. It is most likely that the cells with Ni/GDC anodes did not suffer from carbon deposition under the wet conditions studied. Dry tar-containing syngas for SOFCs is unlikely to cause carbon formation under a mild current load; however, it may induce carbon formation at open circuit. The effect of carbon dioxide that is capable of suppressing carbon deposition was experimentally investigated, and an enhanced performance was observed under the conditions studied. Under carbon risk-free operating conditions, the cell voltage increases when raising the feeding tar concentration, indicating that tar performs as fuel for SOFCs.
Anode recirculation, which is generally driven by an ejector, is commonly used in solid oxide fuel cell (SOFC) systems that operate with natural gas. Alternative fuels such as gasification syngas ...from biomass have been proposed for potential use in the SOFC systems because of the fuel flexibility of SOFCs and the sustainability of biomass resources. Because the ejector was initially designed to use natural gas, its recirculation behavior when using alternative fuels is not well understood. The aim of this research work is to study anode recirculation behavior and analyze its effect on safety issues regarding carbon deposition and nickel oxidation and the performance of an SOFC system fed with gasification syngas under steady state operation. We developed a detailed model including a recirculation model and an SOFC stack model for this study, which was well validated by experimental data. The results show that the entrainment ratio with the gasification syngas is much smaller than that with the natural gas, and the gasification syngas does not have the tendency toward carbon deposition or nickel oxidation under the operating conditions studied. In addition, the recirculation affects the performance of the SOFC, especially the net electrical efficiency, which could be promoted by 160%.
► The anode recirculation behavior of an SOFC fed with different fuels is examined. ► The impact of recirculation on carbon deposition and nickel oxidation is analyzed. ► A large operating pattern is found in the gasification syngas-fueled SOFC. ► The optimized system integration of an SOFC with a gasifier is identified.
Abstract Background Disease recurrence remains one of the biggest concerns in patients after resection of pancreatic ductal adenocarcinoma (PDAC). Despite (neo)adjuvant systemic therapy, most ...patients experience local and/or distant PDAC recurrence within 2 years. High-level evidence regarding the benefits of recurrence-focused surveillance after PDAC resection is missing, and the impact of early detection and treatment of recurrence on survival and quality of life is unknown. In most European countries, recurrence-focused follow-up after surgery for PDAC is currently lacking. Consequently, guidelines regarding postoperative surveillance are based on expert opinion and other low-level evidence. The recent emergence of more potent local and systemic treatment options for PDAC recurrence has increased interest in early diagnosis. To determine whether early detection and treatment of recurrence can lead to improved survival and quality of life, we designed an international randomized trial. Methods This randomized controlled trial is nested within an existing prospective cohort in pancreatic cancer centers in the Netherlands (Dutch Pancreatic Cancer Project; PACAP) and the United Kingdom (UK) (Pancreas Cancer: Observations of Practice and survival; PACOPS) according to the “Trials within Cohorts” (TwiCs) design. All PACAP/PACOPS participants with a macroscopically radical resection (R0-R1) of histologically confirmed PDAC, who provided informed consent for TwiCs and participation in quality of life questionnaires, are included. Participants randomized to the intervention arm are offered recurrence-focused surveillance, existing of clinical evaluation, serum cancer antigen (CA) 19–9 testing, and contrast-enhanced computed tomography (CT) of chest and abdomen every three months during the first 2 years after surgery. Participants in the control arm of the study will undergo non-standardized clinical follow-up, generally consisting of clinical follow-up with imaging and serum tumor marker testing only in case of onset of symptoms, according to local practice in the participating hospital. The primary endpoint is overall survival. Secondary endpoints include quality of life, patterns of recurrence, compliance to and costs of recurrence-focused follow-up, and the impact on recurrence-focused treatment. Discussion The RADAR-PANC trial will be the first randomized controlled trial to generate high level evidence for the current clinical equipoise regarding the value of recurrence-focused postoperative surveillance with serial tumor marker testing and routine imaging in patients after PDAC resection. The Trials within Cohort design allows us to study the acceptability of recurrence-focused surveillance among cohort participants and increases the generalizability of findings to the general population. While it is strongly encouraged to offer all trial participants treatment at time of recurrence diagnosis, type and timing of treatment will be determined through shared decision-making. This might reduce the potential survival benefits of recurrence-focused surveillance, although insights into the impact on patients’ quality of life will be obtained. Trial registration Clinicaltrials.gov, NCT04875325 . Registered on May 6, 2021.
PDF
